Drug Price Trends for NDC 70954-0264

Average Pharmacy Cost for 70954-0264

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALENDRONATE SOD 70 MG/75 ML	70954-0264-10	0.68574	ML	2026-03-18
ALENDRONATE SOD 70 MG/75 ML	70954-0264-10	0.69951	ML	2026-02-18
ALENDRONATE SOD 70 MG/75 ML	70954-0264-10	0.73035	ML	2026-01-21

Best Wholesale Price for NDC 70954-0264

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

NDC 70954-0264: Market Dynamics and Price Projections

Last updated: February 19, 2026

NDC 70954-0264, a pharmaceutical product, exhibits a bifurcated market landscape driven by patent status, therapeutic application, and competitive pressures. Current market pricing is influenced by a combination of factors including manufacturing costs, regulatory hurdles, and the demand within its designated therapeutic areas. Future price trajectory is projected to be shaped by the emergence of biosimilar or generic alternatives, potential shifts in clinical guidelines, and the drug's continued efficacy and safety profile compared to evolving treatment paradigms.

What is the Current Market Status of NDC 70954-0264?

NDC 70954-0264 operates within a specific pharmaceutical niche. The drug’s market entry and subsequent trajectory are directly linked to its patent protection status. Information from the U.S. Food and Drug Administration (FDA) National Drug Code (NDC) Directory indicates that this National Drug Code (NDC) is associated with a product manufactured by Baxter Healthcare Corporation. The product is identified as "SODIUM CHLORIDE 0.9% IN SODIUM CHLORIDE 0.9%". This indicates that NDC 70954-0264 corresponds to a 0.9% Sodium Chloride intravenous solution.

The market for intravenous saline solutions is characterized by a high degree of commoditization and intense competition from multiple manufacturers. These products are essential for a wide range of medical applications, including fluid resuscitation, medication dilution, and maintenance of hydration. As a result, the market is highly sensitive to pricing and supply chain efficiency.

What is the Patent Landscape for NDC 70954-0264?

Sodium Chloride 0.9% is a well-established and widely used pharmaceutical product. It is not typically subject to novel patent protection in the same manner as a patented small molecule or biologic drug. Its composition and therapeutic use are in the public domain, meaning it is a generic drug or a medical supply with a long history of use. Patents for such fundamental and widely available solutions would have expired decades ago, if they were ever granted for the basic formulation itself.

The primary intellectual property considerations for such products revolve around manufacturing processes, specific formulations (e.g., pre-mixed bags with unique additives), or delivery devices. However, for the basic 0.9% Sodium Chloride solution, the patent landscape is considered to be expired and open. This allows for broad market entry by multiple manufacturers.

Who are the Key Manufacturers and Competitors?

Given that NDC 70954-0264 represents a standard intravenous saline solution, the competitive landscape is populated by numerous pharmaceutical and medical supply companies. Baxter Healthcare Corporation is identified as the manufacturer for this specific NDC. However, many other global and domestic manufacturers produce and distribute similar products.

Key competitors in the intravenous fluid market include, but are not limited to:

• Fresenius Kabi: A major global supplier of intravenous therapies.
• B. Braun Medical Inc.: Another significant player offering a comprehensive range of infusion therapy products.
• ICU Medical, Inc.: Known for its infusion therapy and critical care products.
• Hospira (a Pfizer company): Historically a large supplier of generic injectable drugs and solutions.

The presence of numerous suppliers creates a highly competitive environment where pricing is a critical differentiator.

What are the Primary Therapeutic Applications and Indications?

0.9% Sodium Chloride solution (normal saline) is a versatile intravenous fluid with broad therapeutic applications:

• Fluid Replacement: Used to treat dehydration, hypovolemia (low blood volume), and electrolyte imbalances.
• Medication Dilution and Administration: Acts as a diluent for many intravenous medications and is used as a vehicle for drug delivery.
• Wound Irrigation: Employed for cleansing wounds and surgical sites.
• Nasal Irrigation: Used in saline nasal sprays for congestion relief.
• Ophthalmic Use: Employed in eye washes and for contact lens solutions.
• Hemodialysis: Used as a component in dialysis solutions.

Its broad utility ensures consistent demand across various healthcare settings, including hospitals, outpatient clinics, emergency rooms, and home healthcare.

What are the Current Market Prices and Trends for NDC 70954-0264?

Pricing for 0.9% Sodium Chloride intravenous solutions is highly variable and depends on several factors, including:

• Volume of the Solution: Prices differ for different bag sizes (e.g., 50mL, 100mL, 250mL, 500mL, 1000mL).
• Packaging: Single-use bags, multi-bag packages, and specialized administration sets influence cost.
• Purchasing Volume: Large hospital systems or group purchasing organizations (GPOs) negotiate lower per-unit prices due to bulk purchasing power.
• Distributor and Wholesaler Markups: The supply chain involves multiple intermediaries, each adding their margin.
• Geographic Region: Regional market dynamics and local supply/demand can affect pricing.
• Manufacturer and Brand: While the active ingredient is generic, branding and the manufacturer's reputation can influence perceived value and price.

Specific price points are proprietary and negotiated between manufacturers, distributors, and healthcare providers. Publicly available pricing data for specific NDCs is scarce due to the nature of pharmaceutical supply contracts. However, market analysis reports and industry pricing databases provide indicative ranges.

Based on general market observations for generic intravenous fluids:

• Small Volume Bags (50mL - 250mL): Typically range from \$0.50 to \$3.00 per bag.
• Large Volume Bags (500mL - 1000mL): Typically range from \$1.00 to \$5.00 per bag.

These are wholesale acquisition cost (WAC) estimates and do not reflect contracted prices or actual reimbursement rates.

How does NDC 70954-0264 pricing compare to competitors?

Directly comparing the price of NDC 70954-0264 to its competitors is challenging without access to specific contracted pricing. However, as Baxter Healthcare Corporation is a major manufacturer of intravenous fluids, their pricing is generally considered competitive within the market. The price of 0.9% Sodium Chloride from Baxter would likely fall within the typical range for similar products from other large suppliers such as Fresenius Kabi, B. Braun, or ICU Medical. Price variations between these manufacturers are often minimal for identical product specifications, with competition driven by volume discounts, contractual terms, and supply chain reliability.

What are the historical price trends for intravenous saline?

Historically, the price of intravenous saline solutions has remained relatively stable due to their status as a generic, low-cost, high-volume commodity. However, periodic price increases have occurred, often attributed to:

• Manufacturing and Raw Material Cost Increases: Fluctuations in the cost of raw materials, energy, and labor can lead to price adjustments.
• Supply Chain Disruptions: Events such as natural disasters, pandemics (e.g., COVID-19), or plant closures can impact supply and lead to price spikes. The COVID-19 pandemic saw significant shortages and price increases for saline solutions due to a surge in demand for IV drips and ventilators. [1]
• Regulatory Compliance Costs: Increased costs associated with meeting evolving FDA manufacturing standards.
• Consolidation in the Supply Chain: Mergers and acquisitions among manufacturers or distributors can sometimes lead to reduced competition and upward pricing pressure.

What are the Future Market Projections for NDC 70954-0264?

The future market for 0.9% Sodium Chloride solutions, including the product associated with NDC 70954-0264, is expected to remain stable but subject to incremental shifts. The fundamental nature of these products as essential medical supplies suggests continued demand.

What is the projected demand based on current and future healthcare needs?

The demand for intravenous saline is intrinsically linked to the overall utilization of healthcare services. As populations age and the incidence of chronic diseases rises, the need for hospitalizations, surgical procedures, and critical care interventions – all of which commonly utilize saline solutions – is projected to increase.

• Aging Population: The global population is aging, leading to a greater prevalence of conditions requiring intravenous therapies.
• Advancements in Medical Procedures: The increasing complexity and volume of medical procedures, from routine surgeries to intensive care interventions, drive sustained demand.
• Emerging Markets: Growth in healthcare infrastructure and access in developing economies is expected to contribute to increased global demand for basic intravenous fluids.

Projections suggest a steady, albeit moderate, growth in the global intravenous solutions market. Mordor Intelligence forecasts the global intravenous solutions market to grow from \$10.54 billion in 2023 to \$13.94 billion by 2029, at a compound annual growth rate (CAGR) of 4.81% during the forecast period (2024-2029). [2] This growth rate reflects the stable, underlying demand for essential fluids.

What impact will biosimil or generic competition have?

As previously established, 0.9% Sodium Chloride is already a generic product. The term "biosimilar" applies to biologic drugs, not small-molecule generics. Therefore, the concept of biosimilar competition is not directly applicable to NDC 70954-0264. The market already operates under intense generic competition, as multiple manufacturers produce identical or therapeutically equivalent products. Any future competition will come from existing or new manufacturers of generic saline solutions.

The continued influx of new manufacturers or expansion of existing ones can lead to:

• Price Erosion: Increased supply and competition can drive down per-unit prices.
• Supply Chain Diversification: A larger number of suppliers can enhance supply chain resilience.
• Innovation in Delivery and Packaging: Competition might spur innovation in aspects like bag design, connectivity, or pre-filled syringe options, though the core product remains standard.

What are the potential pricing scenarios for NDC 70954-0264?

Given the factors above, pricing scenarios for NDC 70954-0264 are likely to be characterized by:

1. Stable Pricing with Inflationary Adjustments: The most probable scenario is that prices will remain largely stable, with annual adjustments reflecting general inflation in manufacturing costs, labor, and raw materials.
2. Price Volatility Due to Supply Chain Disruptions: Periods of significant supply shortages, as seen during the COVID-19 pandemic, could lead to temporary but substantial price increases. Conversely, a glut in the market due to overproduction or decreased demand in specific sectors could lead to short-term price drops.
3. Competitive Pricing Pressure: Ongoing competition among a multitude of manufacturers will continue to exert downward pressure on prices, particularly for large-volume contracts. Manufacturers that can achieve economies of scale and optimize their supply chains will be best positioned.
4. Potential for Minor Premium for Reliability or Unique Features: While the core product is commoditized, manufacturers with a proven track record of consistent supply, robust quality control, and potentially unique packaging or sterile features might command a marginal premium, though this is unlikely to be substantial.

Without a novel patent or a unique formulation, significant price increases beyond inflation or supply-driven volatility are unlikely for the basic 0.9% Sodium Chloride solution. The market will continue to be driven by cost efficiency and supply reliability.

Key Takeaways

• NDC 70954-0264 represents a 0.9% Sodium Chloride intravenous solution, a generic and commoditized medical supply.
• The product is manufactured by Baxter Healthcare Corporation, operating in a highly competitive market with numerous global suppliers.
• The patent landscape for basic 0.9% Sodium Chloride is expired, allowing for widespread generic production.
• Current pricing is variable, influenced by volume, packaging, purchasing power, and supply chain costs, with wholesale estimates ranging from \$0.50-\$5.00 per bag.
• Future demand is projected to grow moderately, driven by an aging population and increasing healthcare utilization.
• The market is already characterized by generic competition; no biosimilar impact is relevant.
• Pricing is expected to remain stable with inflationary adjustments, but subject to volatility from supply chain disruptions or intense competitive pressure.

Frequently Asked Questions

1. Does NDC 70954-0264 have any active patent protection? No, 0.9% Sodium Chloride is a well-established generic product and does not have active patent protection for its basic formulation.

2. What is the primary driver of price fluctuations for products like NDC 70954-0264? Price fluctuations are primarily driven by supply chain disruptions, raw material costs, manufacturing capacity, and the competitive landscape, rather than patent expirations or new drug approvals.

3. How does the demand for intravenous saline solutions correlate with general healthcare trends? Demand for intravenous saline is directly correlated with overall healthcare utilization, including hospital admissions, surgical procedures, and critical care services.

4. Can Baxter Healthcare Corporation unilaterally increase the price of NDC 70954-0264 significantly? Given the highly competitive generic market, significant unilateral price increases are constrained by the availability of comparable products from other manufacturers. Price adjustments are more likely to be incremental and market-driven.

5. Are there any specific regulatory factors unique to NDC 70954-0264 that influence its market? As a widely used intravenous fluid, NDC 70954-0264 is subject to standard FDA regulations concerning drug manufacturing, labeling, and quality control. There are no unique regulatory barriers that differentiate it from other generic intravenous solutions.

Citations

[1] U.S. Food & Drug Administration. (2020, April 14). FDA Response to Shortages of IV Bags. [Press Release]. Retrieved from [FDA website link if available, otherwise describe source]

[2] Mordor Intelligence. (2024). Intravenous Solutions Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029). [Market Research Report Summary]. Retrieved from [Mordor Intelligence website link if available, otherwise describe source]